ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia
暂无分享,去创建一个
Dagmar Galter | M. Anvret | D. Galter | L. Olson | S. Buervenich | Maria Anvret | Lars Olson | Silvia Buervenich | Andrea Carmine | A. Carmine
[1] R. Pontcharraud,et al. Effects of 4-hydroxynonenal, a lipid peroxidation product, on dopamine transport and Na+/K+ ATPase in rat striatal synaptosomes , 1998, Neurochemistry International.
[2] P. Dostert,et al. Dopamine-derived alkaloids in alcoholism and in Parkinson's and Huntington's diseases , 2005, Journal of Neural Transmission.
[3] G. Sedvall,et al. NURR1 mutations in cases of schizophrenia and manic-depressive disorder. , 2000, American journal of medical genetics.
[4] M. Anvret,et al. Alcohol dehydrogenase alleles in Parkinson's disease , 2000, Movement disorders : official journal of the Movement Disorder Society.
[5] M. O’Donovan,et al. Changes in dopa decarboxylase mRNA but not tyrosine hydroxylase mRNA levels in rat brain following antipsychotic treatment , 2005, Psychopharmacology.
[6] J. Holden,et al. Effects of Catechol-O-methyltransferase Inhibition on the Rates of Uptake and Reversibility of 6-Fluoro-l-Dopa Trapping in MPTP-induced Parkinsonism in Monkeys , 1997, Neuropharmacology.
[7] R. Little,et al. Partial Purification and Properties of Human Brain Aldehyde Dehydrogenases , 1985, Journal of neurochemistry.
[8] U. Dräger,et al. Retinoic acid synthesizing enzymes in the embryonic and adult vertebrate. , 1995, Advances in experimental medicine and biology.
[9] G. Jonsson,et al. FLUORESCENCE METHODS FOR THE HISTOCHEMICAL DEMONSTRATION OF MONOAMINES: 4. HISTOCHEMICAL DIFFERENTIATION BETWEEN DOPAMINE AND NORADRENALINE IN MODELS , 1965, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[10] C. Barraclough,et al. Effects of reserpine on tyrosine hydroxylase mRNA levels in locus coeruleus and medullary A1 and A2 neurons analyzed by in situ hybridization histochemistry and quantitative image analysis methods. , 1992, Brain research. Molecular brain research.
[11] N. Hattori,et al. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[12] B J Hoffer,et al. Dopamine neuron agenesis in Nurr1-deficient mice. , 1997, Science.
[13] J. Parkinson. An Essay on the Shaking Palsy , 2002 .
[14] R. Satran,et al. Disulfiram (Antabuse) psychosis. , 1967, The American journal of psychiatry.
[15] Y. Mizuno,et al. Inhibition of mitochondrial respiration by 1,2,3,4-tetrahydroisoquinoline-like endogenous alkaloids in mouse brain , 1990, Neurochemical Research.
[16] U. Dräger,et al. High levels of a retinoic acid-generating dehydrogenase in the meso-telencephalic dopamine system. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[17] A Carlsson,et al. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. , 2001, Annual review of pharmacology and toxicology.
[18] D. Petersen,et al. Metabolism of malondialdehyde by rat liver aldehyde dehydrogenase. , 1983, Toxicology and applied pharmacology.
[19] L. Olson,et al. Retinoid X receptor heterodimerization and developmental expression distinguish the orphan nuclear receptors NGFI-B, Nurr1, and Nor1. , 1996, Molecular endocrinology.
[20] W. Burke,et al. Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria. , 2001, Free radical biology & medicine.
[21] W. Burke,et al. 3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis. , 2001, Brain research. Molecular brain research.
[22] T. Nagatsu,et al. An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions , 1988, Neuroscience Letters.
[23] E. Mendez-Alvarez,et al. Reduction of rat brain levels of the endogenous dopaminergic proneurotoxins 1,2,3,4-tetrahydroisoquinoline and 1,2,3,4-tetrahydro-β-carboline by cigarette smoke , 2001, Neuroscience Letters.
[24] Steven A. Johnson,et al. Tyrosine Hydroxylase mRNA Concentration in Midbrain Dopaminergic Neurons Is Differentially Regulated by Reserpine , 1990, Journal of neurochemistry.
[25] H. Braak,et al. Nigral and extranigral pathology in Parkinson's disease. , 1995, Journal of neural transmission. Supplementum.
[26] G. Duester. Genetic dissection of retinoid dehydrogenases. , 2001, Chemico-biological interactions.
[27] Murthy Kk. Psychosis during disulfiram therapy for alcoholism. , 1997 .
[28] A. Carlsson,et al. 3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists , 1957, Nature.
[29] T. Montine,et al. 4‐Hydroxy‐2‐Nonenal Pyrrole Adducts in Human Neurodegenerative Disease , 1997, Journal of neuropathology and experimental neurology.
[30] L. Olson,et al. Fate of mesencephalic AHD2-expressing dopamine progenitor cells in NURR1 mutant mice. , 1999, Experimental cell research.
[31] Kurt Jellinger,et al. Amygdala pathology in Parkinson's disease , 2004, Acta Neuropathologica.
[32] O. Hornykiewicz. [The tropical localization and content of noradrenalin and dopamine (3-hydroxytyramine) in the substantia nigra of normal persons and patients with Parkinson's disease]. , 1963, Wiener klinische Wochenschrift.
[33] D. Calne. Developments in the pharmacology and therapeutics of parkinsonism , 1977, Annals of neurology.
[34] T. Niwa,et al. Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: The behavioral and biochemical changes , 1990, Neuroscience Letters.
[35] A. Kingsbury,et al. The vulnerability of nigral neurons to Parkinson's disease is unrelated to their intrinsic capacity for dopamine synthesis: An in situ hybridization study , 1999, Movement disorders : official journal of the Movement Disorder Society.
[36] T. Nagatsu,et al. Parkinsonism produced by tetrahydroisoquinoline (TIQ) or the analogues. , 1993, Advances in neurology.
[37] T. Hökfelt,et al. Sensitive mRNA detection using unfixed tissue: combined radioactive and non-radioactive in situ hybridization histochemistry , 1992, Histochemistry.
[38] S. Lightman,et al. Neuropeptide Y and tyrosine hydroxylase mRNA levels in the locus coeruleus show similar increases after reserpine treatment , 1991, Neuropeptides.
[39] A. Pictet,et al. Über die Bildung von Isochinolin‐derivaten durch Einwirkung von Methylal auf Phenyl‐äthylamin, Phenyl‐alanin und Tyrosin , 1911 .
[40] M. Selley. (E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. , 1998, Free radical biology & medicine.
[41] H Bratzke,et al. Neuropathological hallmarks of Alzheimer's and Parkinson's diseases. , 1998, Progress in brain research.
[42] J. Scher. Psychotic reaction to disulfiram. , 1967, JAMA.
[43] S. Paul,et al. Tyrosine hydroxylase and cholecystokinin mRNA levels in the substantia nigra, ventral tegmental area, and locus ceruleus are unaffected by acute and chronic haloperidol administration , 1990, Cellular and Molecular Neurobiology.
[44] A. Yoshida,et al. Retinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenase. , 1992, Enzyme.
[45] H. Esterbauer,et al. Metabolism of the lipid peroxidation product 4-hydroxynonenal by isolated hepatocytes and by liver cytosolic fractions. , 1985, The Biochemical journal.
[46] Eriksson Cj. Regulation of acetaldehyde metabolism during ethanol oxidation in perfused rat liver. , 1977 .
[47] M. Collins. Neuroamine condensations in human subjects. , 1980, Advances in experimental medicine and biology.
[48] A. Graybiel,et al. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. , 1999, Brain : a journal of neurology.
[49] L. Olson,et al. Cellular expression of the immediate early transcription factors Nurr1 and NGFI-B suggests a gene regulatory role in several brain regions including the nigrostriatal dopamine system. , 1996, Brain research. Molecular brain research.
[50] A. Yoshida,et al. Structural mutation in a major human aldehyde dehydrogenase gene results in loss of enzyme activity. , 1982, American journal of human genetics.
[51] A. Yoshida,et al. Genomic structure of the human cytosolic aldehyde dehydrogenase gene. , 1989, Genomics.